PHILADELPHIA, PENNSYLVANIA
Pharmaceuticals
2
$310K
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-13 | New offering first sale 2026-09-25 | $185K | $500K | details · SEC filing |
| 2024-01-16 | New offering first sale 2024-01-08 | $125K | $1.50M | SEC filing |
Watch EpiVario Inc.
Get an email when EpiVario Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with EpiVario Inc.?
Who to contact
- Thomas Kim — Executive Officer, Director
- Christopher Cashman — Director
- Eric Schultenover — Director
- Round: Form D filed 2026-10-13
- Amount sold: $185K
- Industry: Pharmaceuticals
- Based: PHILADELPHIA, PENNSYLVANIA
People listed
- Thomas Kim — Executive Officer, Director
- Christopher Cashman — Director
- Eric Schultenover — Director
- Filing: Form D filed 2026-10-13
- Amount sold: $185K
- Industry group: Pharmaceuticals
- Based: PHILADELPHIA, PENNSYLVANIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when EpiVario Inc. raises, hires or launches. No email unless you switch it on.
Watch EpiVario Inc. →Want the whole picture on EpiVario Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on EpiVario Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on EpiVario Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from EpiVario Inc.'s own filings with the SEC. The people those filings name are on the team page.